Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study
- 4 November 2005
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 19 (16) , 1934-1936
- https://doi.org/10.1097/01.aids.0000189569.10471.b4
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patientsAIDS, 2004
- Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.Journal of Antimicrobial Chemotherapy, 2002
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002
- Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced PatientsThe Journal of Infectious Diseases, 2002
- ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus ProteaseAntimicrobial Agents and Chemotherapy, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Decline in deaths from AIDS due to new antiretroviralsThe Lancet, 1997